TPatients and Pharma want the same thing, but for different reasons. Patients want access, support and information about the latest drugs while Pharma needs market access for sales and profits that will to fund more research. So, they are natural bedfellows....?
Patient pressure and influence across the range of Pharma's activities is growing. While Patient Advocacy Groups are well established, there is a new breed of patient, empowered by the digital revolution, and with access to a wide-range of clinical and health data. These advocates share information and experiences with fellow patients, are informed about their condition, keen to take an informed part in their diagnosis and treatment, and are no longer willing to abdicate decision-making to health professionals.
Collectively, they have political weight, independence and a high social profile: so what do patients want – and expect – from Pharma?
Talking the talk
For its part, Pharma speaks the language of patient-centricity but doesn't always deliver. Bound by regulations in many countries limiting what can, and cannot, be communicated to patients or put in the public domain, industry has struggled to square demands for more openness with regulatory regimes that actively limit its ability to communicate with end-user customers. That could be a generous interpretation: perhaps getting too close to patients presents unacceptable risk to reputation, independence, and the prevailing business model.
Whatever Pharma does, it will meet with concern that when profit is part of the health equation, then its motives can be questioned. The funding of patient groups and related patient focused initiatives leaves Pharma open to the accusation that by encouraging "pester power" and patient pressure on health payers and Health-Technology Assessment bodies, it can achieve what it is unable to do through normal regulatory channels: encourage reimbursement and product uptake while driving sales.
Time to catch up
With the community and voice the internet has given patients, demand for information and dialogue is developing rapidly. The industry's response – whether by choice or regulatory burden – has not. If the common aims of patients and Pharma are to be truly mutually beneficial, the industry has to up its patient–relations game.
Essential insight in this new report: Pharma-Patient Engagement
This closely argued and concise management report from FirstWord combines keen market observations with the insights of leading players in patients groups. It presents a compelling analysis of the issues and examines key drivers such as:
For senior management, marketing and communication executives, this report is a timely reminder that industry must do more to harness and engage with the rapidly growing power of the patient.
Insights from the report
"Provide the patient groups with independent funding to do what patients really need, instead of doing your own programmes and failing on their compliance, restrictions and barriers. Rather than spending so much money on these kinds of single-sponsor awareness programmes, why doesn't industry set up a fund to support organizations with core funding, removing any suspicion of undue influence?" Jan Geissler, cancer survivor, patient advocate and Director of the European Patients Academy on Therapeutic Innovation (EUPATI)
"I would say from this point onwards, pharma should expect to see much more feedback and much more pressure from patient-driven social media platforms, patient groups, around what they do, how they act, their models, their pricing and so on, and as a result will be forced to become more transparent and to justify things much more than they have been in the past," Eric Low, Chief Executive, Myeloma UK
"We patients want to have the keys to the car. We patients want to be in control of our own destiny with the pharmaceutical industry, with hospitals – with physicians truly being our consultants in an adult-to-adult relationship, not a parent/child relationship." Andrew Schorr, patient advocate and founder of Patient Power LLC
"It's always better to have support from as many companies as possible. Otherwise, the perception is that you're in the pocket of one company." Lizzie Graham, Director of Fundraising and Global Communications, the European Parkinson's Disease Association
Use this report to:
Table of Contents
for Pharma-Patient Engagement: insights from patient opinion leaders [Published by FirstWord Pharma]
2.Empowered, aware patients
3.The pharma-patient relationship
3.1.Overlapping agendas in healthcare
3.2.Access to medicines
3.4.Communality of interests between patients and industry
3.5.Clinical-trial data transparency
3.6.Patient organisation fears of co-option
3.7.The effect of corporate reputation on relationships
3.8.Financial influence on patient groups
3.9.Emphasis on transparency
4.Programme and funding challenges
5.Recognise the interests of various stakeholders
5.1.Market conditions count
5.2.The call for free and frank discussion
5.3.Underlying concerns about the relationship
5.4.A mutually beneficial overlap of interests
6.2.Remodelling the interface between patients and industry
6.3.What do patients want?
6.4.Understanding the patient body
7.The impact of digital
7.1.Reaching beyond patient organisations
7.2.AllTrials and transparency
7.3.The business of pharmaceuticals
7.4.Pharma's social media lag
7.5.The patient thirst for information
7.6.The internet of things
7.7.The role of medical apps
7.9.Pharma's reluctance to engage with patients
7.10.A new sphere of influence created by patient advocates online
8.The dynamics of patient empowerment and market change
8.1.does industry fit in?
8.2.Information needs beyond benefit-risk
8.3.Patients want information, not promotion
8.4.A relationship based on trust
8.5.Differences of interpretation can lead to confusion
8.6.Using third parties to provide information
9.How to engage with patient groups
9.1.You have to let go of the marketing
9.2.Information and engagement
9.3.A contribution to life and lifestyle
9.4.A conversation of equals
9.5.Talking and listening are both important
9.6.It comes back to trust
9.7.Addressing patient needs
9.8.Engaging early in R&D
9.9.Engaging with patients from top to bottom
10. Actively involving patients in R&D
10.1.Case study: the EUPATI project
10.2.Inolvement in R&D is selective
10.3.More expertise is needed
11.Case study: EPDA encourages national engagement
12.Conclusion: stepping up to the plate
|Title||Date Published||Price from||More Details|
| Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs|
IntroductionIt’s time to click on this.The media’s dubbed them ‘a doctor in your pocket’ and ‘health...
|01 Feb 2013 by FirstWord Pharma||USD $591 (normally
| Big Data in Pharma Marketing|
IntroductionBig data - the huge volume of digital data generated worldwide - continues to grow expon...
|01 Jan 2013 by FirstWord Pharma||USD $591 (normally
| Social and Mobile Pharma - the State of the Digital Landscape|
IntroductionTightly-regulated and conservative in outlook, the pharmaceutical industry has largely b...
|01 Nov 2012 by FirstWord Pharma||USD $591 (normally
| Pharma and Payers – Building Better Relationships|
IntroductionChanges in the healthcare landscape have put payers (public and private) under mounting ...
|01 Sep 2012 by FirstWord Pharma||USD $591 (normally
| Pharma Reputations: Managing Perceptions|
IntroductionPharma is no stranger to the idea of nurturing and defending corporate reputations. But...
|01 Aug 2012 by FirstWord Pharma||USD $548 (normally
| Pharma's Future Role in CME|
IntroductionOver the last 10 years, every aspect of continuing medical education (CME) has endured m...
|01 Aug 2012 by FirstWord Pharma||USD $591 (normally
| Pharma sales force shape, size and structure — where next?|
IntroductionRetarget your sales force with new resourcesSales force management now plays a critical ...
|01 Jul 2012 by FirstWord Pharma||USD $591 (normally
| Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma|
IntroductionIn 2009, China’s government announced plans to invest RMB1.13 trillion (0 billion) in...
|01 Jun 2012 by FirstWord Pharma||USD $846 (normally
| Meeting KOL Needs: What Pharma Needs to Know|
IntroductionThe role of the Key Opinion Leader (KOL) has changed over the past 30 years. And it's ab...
|01 Feb 2012 by FirstWord Pharma||USD $1,228 (normally
| Academic Detailing: Pharma Fights Back|
IntroductionEver since it was introduced three decades ago, academic detailing—which now increasingl...
|01 Jan 2012 by FirstWord Pharma||USD $633 (normally
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.